Truvada

(redirected from emtricitabine and tenofovir disoproxil fumarate)
Also found in: Medical.

Tru·va·da

 (tro͞o-vä′də)
A trademark for a drug consisting of a combination of emtricitabine and a prodrug of tenofovir.
References in periodicals archive ?
Contract awarded for event 2623/2016 emtricitabine and tenofovir disoproxil fumarate coated tablets 300mgs + 200 mgs.
Belal, "New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate," Arabian Journal of Chemistry, 2013.
Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) said on Tuesday that it has filed the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults in Europe.
In October 2011, Gilead filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for marketing approval of the Quad, a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV.
2% controlling interest, has received the first tentative approval from the Food and Drug Administration under the President's Emergency Plan for AIDS Relief for its abbreviated new drug application for emtricitabine and tenofovir disoproxil fumarate tablets, 200 mg/300 mg.
The most common adverse drug reactions to emtricitabine and tenofovir disoproxil fumarate (incidence 10%) were diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.
Emtricitabine and tenofovir disoproxil fumarate, two previously approved antiviral drugs is added in the pill currently sold as the combination pill Truvada.
28 October 2011 - US biopharmaceutical company Gilead Sciences Inc (NASDAQ:GILD) said that it has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for marketing approval of the Quad, a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Stribild combines four compounds in one daily tablet: elvitegravir, an integrase inhibitor; cobicistat, a pharmacoenhancing agent; emtricitabine and tenofovir disoproxil fumarate.
The combination of emtricitabine and tenofovir disoproxil fumarate, approved in 2004 and marketed as Truvada, blocks the action of another enzyme that HIV needs to replicate in a person s body.
15 August 2011 - US biopharmaceutical company Gilead Sciences Inc (NASDAQ:GILD) said today that a Phase III clinical trial (Study 102) of its fixed-dose, single-tablet Quad regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naive patients, has met its primary objective, which was non-inferiority at week 48 as compared to Atripla.
Stribild, referred to as "Quad" prior to FDA approval, combines four compounds in one daily tablet: elvitegravir, an integrase inhibitor; cobicistat, a pharmacoenhancing agent; emtricitabine and tenofovir disoproxil fumarate.